What Links Inflammation and Depression? A Clinician’s Perspective
Medically reviewed by Paul Hornsey
Table of Contents
- Emerging Evidence at the Intersection of Inflammation and Depression
- Why Is Inflammation Relevant to Depression Treatment?
- From Biomarkers to Practice: Emerging Interventions in Inflammation and Depression
- From Insight to Action: Evolving Pathways for Inflammation and Depression
- Reflecting on the Path Ahead
Emerging Evidence at the Intersection of Inflammation and Depression
Depression is increasingly being explored through a dual lens: not only as a psychological disorder, but as one with significant inflammatory underpinnings. Over recent years, research into the biological basis of Major Depressive Disorder (MDD) has uncovered consistent patterns of a potential involvement of inflammation1-5, prompting renewed clinical attention, particularly in cases of treatment-resistant depression.
But how inflammation and depression are linked is complex and multifaceted. One hypothesis suggests that for some, persistent depressive symptoms may be underpinned by chronic immune activation. This theory is supported by robust findings of elevated inflammatory markers in individuals with depression – particularly C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α).
What markers are elevated in cases of inflammation and depression?
CRP has been among the most widely studied marker that links inflammation and depression. In most analyses, higher blood levels of CRP correlate with greater depression symptom severity6-7, a more distinct pattern of depressive symptoms, and a poorer treatment response6. One study found that elevated CRP levels were significantly associated with greater overall Montgomery–Åsberg Depression Rating Scale scores among women, suggesting a possible role for sex-linked biological or psychosocial immune modulation7. These findings align with the “sickness syndrome” hypothesis, proposing that low-grade inflammation may characterise a distinct depression subtype7.
Similarly, IL-6 has emerged as one of the most reliable inflammatory markers associated with MDD9-10. Its elevation has been observed in both blood and cerebrospinal fluid samples of patients with depression2,12-13. The proposed biological mechanisms are complex, however, but include disruption of neurotransmitter metabolism and activation of the hypothalamic–pituitary–adrenal (HPA) axis 9.
TNF-α has too been implicated14-15. It may influence depressive symptoms via several mechanisms; HPA axis activation, altered serotonin transporter function, and tryptophan depletion via stimulation of indoleamine 2,3-dioxygenase, which leads to tryptophan depletion14-15.
The use of anti-inflammatory agents
This growing body of evidence has led to early trials of anti-inflammatory agents – including NSAIDs, minocycline, and cytokine inhibitors – as adjunctive treatments for depression, alongside antidepressants16-19. Notably, findings suggest these agents may enhance treatment response without increasing risks of gastrointestinal, muscular, or cardiovascular side effects16-17.
The impact of the gut-brain axis in inflammation and depression
Interest is also building around the gut–brain axis and its role in inflammatory signalling20-23. The gut and brain are both highly responsive sensory systems that continuously integrate immune and environmental signals20. Dysbiotic gut microbiota has been linked to neuroinflammation and psychiatric disorders, likely due to its influence on immune homeostasis and permeability of the blood–brain barrier21-22.
Taken together, this literature points to a compelling possibility: that inflammation may not only correlate with depressive symptoms but may also contribute to their resistance to conventional treatment. For clinicians, this opens new lines of enquiry, both in assessment and intervention, particularly for patients whose symptom profiles defy standard diagnostic frameworks.
Why Is Inflammation Relevant to Depression Treatment?
In clinical settings, it is not uncommon to encounter individuals with depression whose presentations resist clear categorisation, and whose response to standard treatments proves limited or inconsistent. Many have already trialled multiple medications and psychotherapeutic approaches, only to find themselves navigating the same cyclical symptoms with little sustained relief. For these people, inflammation may offer a clinically relevant lens through which to understand treatment resistance24-25.
Indeed, the most treatment-resistant individuals consistently show higher levels of inflammatory biomarkers, with inflammation predicting poorer long-term outcomes even after inpatient care25. Some findings also suggest that specific inflammatory markers, such as IL-6, may help identify patients less likely to respond to conventional antidepressants25. The implications are significant, since this offers clinicians a way to better stratify cases that might otherwise be written off as complex or refractory – using inflammation and depression to connect biological signals to psychological outcomes.
This line of research also introduces pragmatic interventions that can be incorporated without delay. The Johns Hopkins anti-inflammatory diet, for example, reflects a broader shift towards lifestyle medicine as part of a multidisciplinary, integrated approach to care26. For certain patients, such “low hanging fruit” lifestyle alterations like these may meaningfully reduce symptom load or augment pharmacological and psychotherapeutic outcomes.
This is particularly pertinent for high-functioning individuals whose depressive symptoms manifest less as emotional collapse and more as cognitive fatigue, irritability, or somatic malaise. The inflammation hypothesis provides a compelling physiological explanation for such cases, as it bridges the gap between what we observe in clinic and what we now understand from the bench25.
For healthcare professionals, this evolving field encourages deeper curiosity, reframes diagnostic pathways, and strengthens referral logic in the pursuit of more effective, tailored care.
From Biomarkers to Practice: Emerging Interventions in Inflammation and Depression
For too long, inflammation has been considered an adjunct issue in psychiatry – a peripheral concern, rather than a core component of mental health assessment. But this view may realistically no longer serve us. As evidence grows, the need to consider immunological profiles, immune-related comorbidities, and lifestyle factors as part of routine evaluation for depression is becoming increasingly difficult to ignore.
The idea of tailoring care based on inflammatory biomarkers is becoming more compelling as more research emerges. It offers the prospect of targeted interventions that move beyond the limitations of trial-and-error pharmacology. Adjunctive treatment with anti-inflammatory agents may hold real promise for individuals who haven’t responded to conventional antidepressants, especially where elevated inflammatory markers are present26. This opens the door to more integrated care pathways; those that align psychiatry more closely with internal medicine and immunology.
Yet, it is equally important to acknowledge the limitations. The field is still in its early stages, and the causal relationship between inflammation and depression remains complex. Depression is not a single disorder but a heterogeneous syndrome, and studies can suffer from methodological and sample-based limitations. It’s key here to highlight just how much of the anti-inflammatory intervention literature is still based on preliminary or early-phase trials (see27 for examples).
Nevertheless, novel directions are emerging. Gut-brain microbiota modulation is under increasing scrutiny, with some studies suggesting the benefit to symptoms following faecal microbiota transplantation28-29. Metabolic screening and personalised immune-psychiatric profiling are also beginning to surface in both research and clinical conversation30-32.
For practitioners, the task is to hold both perspectives at once: to act on what is clinically actionable today, while remaining critically engaged with what is still under development. The link between inflammation and depression is not a silver bullet – anything seldom is – but it may well become an essential strand in the fabric of personalised mental health care.
From Insight to Action: Evolving Pathways for Inflammation and Depression
If inflammation contributes meaningfully to depressive symptomatology – particularly in those with fatigue, anhedonia, or emotional blunting that has proven unresponsive to SSRIs or CBT – then clinical pathways must begin to reflect that. In such cases, selective screening for markers like CRP or IL-6 could offer valuable insight into underlying physiological drivers.
But, as usual, multidisciplinary collaboration is central to this shift. Psychiatry cannot remain siloed if we are to meet complex needs. Integrated care models – in which mental health teams liaise with rheumatology, endocrinology, nutrition, microbiome specialists and exercise medicine – offer a more precise and collaborative route forward.
As this approach matures, referral pathways may evolve. Individuals presenting with both treatment resistance and elevated inflammatory markers may benefit from being triaged into immune-psychiatric or metabolic-informed services. It is here that psychiatry begins to share clinical space with internal medicine.
However, this is not a call for routine screening across all presentations. Blanket testing would risk both overreach and ambiguity. Instead, targeted assessment for those at higher risk – whether due to chronic immune conditions, lifestyle factors, or atypical response patterns – allows for more meaningful and proportionate clinical decision-making.
In time, an interesting direction could include clinical guidelines that incorporate structured algorithms and various artificial intelligence-based screening to guide such decisions with lifestyle interventions perhaps recommended as first-line adjunctive care in inflammation-linked depression.
Reflecting on the Path Ahead
Inflammation is unlikely to eclipse serotonin as the prevailing neurochemical narrative – but it does extend our understanding in clinically meaningful ways. It brings the body back into focus. For those presenting with persistent, treatment-resistant symptoms, this broader lens can be essential.
It’s key here to draw out the fact that Inflammation and depression are not always linked. But when they are, recognising that connection may prevent years of inadequate treatment or misunderstood distress.
As evidence evolves, so too should our practices. A whole-body assessment model – inclusive of immune and metabolic health – requires thoughtful, cross-disciplinary collaboration. Psychiatry must partner not only with psychology, but with medicine more widely.
At Harbor, our tailored care pathways allow for just that. Explore how our private and residential programmes are already integrating a myriad of psychological, physiological, and lifestyle-informed care practises that are helping to reshape recovery for those who need it most.
